Last reviewed · How we verify
Active Ankylosing Spondylitis — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Induction- PF-06480605 450 mg SC Q4W | induction-pf-06480605-450-mg-sc-q4w | Pfizer | small molecule | IL-17 receptor | ||
| tumor necrosis factor inhibitors (TNFi) | tumor-necrosis-factor-inhibitors-tnfi | Pfizer | biologic | tumor necrosis factor | ||
| TNF Inhibitor | tnf-inhibitor | Pfizer | Monoclonal Antibody | TNF-alpha |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 3 drugs in Active Ankylosing Spondylitis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Active Ankylosing Spondylitis:
- Active Ankylosing Spondylitis treatment updates — RSS
- Active Ankylosing Spondylitis treatment updates — Atom
- Active Ankylosing Spondylitis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Active Ankylosing Spondylitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/active-ankylosing-spondylitis. Accessed 2026-06-10.
Related
- Active Ankylosing Spondylitis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing